I originally published this guideline update in 2021 on Dapagliflozin use in heart failure. NICE has now released new guidance advising that empagliflozin can also be used in heart failure. This new guideline was released in Mar 22. The indications for its use are the same as for dapagliflozin. No studies have been done to directly compare the effectiveness of dapagliflozin with empagliflozin.
Further guidance has been released in Jun 2023 (dapagliflozin) and in Nov 2023 (empagliflozin) advising that these drugs can now be used in heart failure with a preserved or mildly reduced ejection fraction. Previously the guidance was that patients had to have a reduced ejection fraction.
How do SGLT-2 inhibitors work in heart failure?
SGLT-2 inhibitors reduce glucose reabsorption in the kidneys.
